Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03199469 · ClinicalTrials.gov registry record · Phase 2
A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)
A Phase 2 study of X-Linked Myotubular Myopathy, sponsored by Astellas Gene Therapies.
- Active
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 6
- Study locations
NCT03199469: Active Phase 2 study of X-Linked Myotubular Myopathy, sponsored by Astellas Gene Therapies.
NCT03199469 is a Phase 2 study of X-Linked Myotubular Myopathy that is active but no longer recruiting, run by Astellas Gene Therapies. The registered enrollment target is 27 participants, below the 31-participant average among 3 other X-Linked Myotubular Myopathy trials with a reported enrollment target (13% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03199469, a Phase 2 study of X-Linked Myotubular Myopathy, is active but no longer recruiting, sponsored by Astellas Gene Therapies.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 6
- Study locations
Study Summary
X-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no therapies for this serious condition. The protein myotubularin is needed for muscle development and movement. A gene called MTM1 tells the body to make myotubularin. XLMTM is caused by changes, or mutations, in the MTM1 gene. Changes in the MTM1 gene causes low levels of myotubularin to be made, so the muscles do not work properly. XLMTM may also affect the liver, and in some cases, this can be dangerous and threaten the patient´s life. Gene therapy is a way of getting a healthy copy of a gene into the body. This allows the body's cells to make a normal protein that may reduce disease symptoms. AT132 is a gene therapy that gets a healthy MTM1 gene into the body to help improve muscle development and function in young children with the disease. AT132 does not treat liver disease, and because of the way the treatment works, it may make liver problems worse. AT132 was the gene therapy treatment given to children who participated in this study and is not available to the public. In this study, AT132 was given to children for the first time. Due to the occurrence of severe complications and fatalities associated with administration of AT132, the study has been stopped and no further participants will be enrolled. The main aim of the study is to check how long young children need machines to support breathing (ventilation support) after AT132. Due to the occurrence of severe complications and fatalities associated with administration of AT132, the study has been stopped and no further participants will be enrolled. This study included children with XLMTM under 5 years old who had breathing problems caused by XLMTM. They couldn't take part if they were born prematurely, recently had surgery, had liver disease or other condition or disease the study doctor thought was medically important. The study did enroll participants
Primary Outcome
The hours of ventilation support were based on diary data from participants for whom diary data was collected at baseline and by assessment of time off ventilator questionnaire for all other participants. Weekly scores were the average of ventilation hours needed for at least 5 out of the 7 days leading up to and including the analysis visit day (e.g., Day 168 for Week 24). For cases where the diary or the ventilator assessment indicated the ventilator type = "None", then zero was imputed for th
Conditions Studied
Interventions
- GENETIC Resamirigene bilparvovec
Study Locations (6)
Other
- Hopital Armad Trousseau - Paris
- Kinderklinik und Kinderpoliklinik im Dr. Von Haunerschen Kinderspital Klinikum der Universitat Munchen - München
California
- UCLA Medical Center - Los Angeles
Illinois
- Ann & Robert H Lurie Children's Hospital of Chicago - Chicago
Maryland
- National Institute of Neurological Disorders and Stroke/NIH Porter - Bethesda
Ontario
- Hospital for Sick Children - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2017-08-02 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 2 |
What the registry record for NCT03199469 still lists
NCT03199469 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 31-participant average among 3 other X-Linked Myotubular Myopathy trials with a reported enrollment target (13% lower).
The record links to 1 condition, with X-Linked Myotubular Myopathy appearing as the primary indexed condition, and to 1 intervention - of which Resamirigene bilparvovec is the first listed.
NCT03199469 lists 6 locations in 5 states (Other, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT03199469 about?
NCT03199469 is a clinical study titled "A Study of AT132 in Young Children With X-Linked Myotubular Myopathy (XLMTM)". X-linked myotubular myopathy (XLMTM) is a rare and serious condition present at birth where the muscles do not work properly. There are currently no therapies for this serious condition. The protein myotubularin is needed for muscle development and movement. A gene called MTM1 tells the body to mak...
What is the current status of trial NCT03199469?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2017-08-02. Estimated completion is 2030-03-31.
What conditions does trial NCT03199469 study?
This clinical trial studies the following conditions: X-Linked Myotubular Myopathy.
What interventions are being tested in trial NCT03199469?
The interventions under investigation include: Resamirigene bilparvovec (GENETIC).
Who is sponsoring clinical trial NCT03199469?
This trial is sponsored by Astellas Gene Therapies, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03199469 being conducted?
This trial has 6 study locations across California, Illinois, Maryland, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for X-Linked Myotubular Myopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI